<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[LabMate - Medium]]></title>
        <description><![CDATA[The official content of LabMate (www.labmate.us). We are a marketplace platform connecting biopharmaceutical companies and investment firms with scientists from top-tier research institutions for short-term consulting projects and full-time employment. - Medium]]></description>
        <link>https://medium.com/labmate?source=rss----85079c8483e6---4</link>
        <image>
            <url>https://cdn-images-1.medium.com/proxy/1*TGH72Nnw24QL3iV9IOm4VA.png</url>
            <title>LabMate - Medium</title>
            <link>https://medium.com/labmate?source=rss----85079c8483e6---4</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Fri, 20 Nov 2026 00:46:04 GMT</lastBuildDate>
        <atom:link href="https://medium.com/feed/labmate" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[New Mansfield, MA Incubator Opens Doors to Life Science Entrepreneurs]]></title>
            <link>https://medium.com/labmate/new-mansfield-ma-incubator-opens-doors-to-life-science-entrepreneurs-17d2d645dfd0?source=rss----85079c8483e6---4</link>
            <guid isPermaLink="false">https://medium.com/p/17d2d645dfd0</guid>
            <category><![CDATA[boston]]></category>
            <category><![CDATA[incubator]]></category>
            <category><![CDATA[startup]]></category>
            <category><![CDATA[biotechnology]]></category>
            <category><![CDATA[life-sciences]]></category>
            <dc:creator><![CDATA[LabMate]]></dc:creator>
            <pubDate>Thu, 31 Aug 2017 12:27:44 GMT</pubDate>
            <atom:updated>2017-09-01T00:41:09.735Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*NH409kOoar-piquhfFyMXw.jpeg" /></figure><blockquote><strong>Note From LabMate:</strong> We are a proud supporter of the Mansfield Bio-Incubator. Resident companies enjoy concierge LabMate services to augment their consulting and recruiting efforts. Learn more here: www.labmate.us</blockquote><h3>New Mansfield, MA Incubator Opens Doors to Life Science Entrepreneurs</h3><p>Over the past decade, Massachusetts has become a worldwide mecca for the life science industry, thanks to a $1 billion life science initiative spearheaded by the former Massachusetts Governor Deval Patrick. Diverse world-class talent pool and groundbreaking research from top-notch institutions such as Harvard, MIT, and other local universities led to an influx of both large biotech/pharma and smaller start-ups into Cambridge. However, while creating a vibrant, round-the-clock culture around Kendall Square, this boom also led to a vacancy rate in single digits and drove up the price to as much as $90 per square foot. The costs and the shortage of the available laboratory space forced many life science companies to move outside the city and create the offshoots of the Cambridge super-cluster in places like Waltham, Watertown, Natick, North Shore, and Worcester.</p><p>One part of Massachusetts that did not reap the full benefits of the life science bonanza is the southeastern region of the state, along with Rhode Island. The area boasts high-quality science programs at the institutions such as Wheaton College, Bridgewater State, and Brown University amongst others, along with larger life science companies such as EMD Serono, Johnson&amp;Johnson, Smith &amp; Nephew, and Medtronic. However, the local lab space availability and job opportunities in Life Sciences remain scarce.</p><p>Mansfield Bio-Incubator was created in 2014 to fill this gap and drive the growth of the life science industry in the region. We are a non-profit organization whose mission is to facilitate and assist the creation, growth, and success of the next generation of biotech companies. We aim to do this by creating a non-elitist community and maintaining the affordable lab and office space and with services, training, education, mentoring, and a network of professional advisers and online scientific communities.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*EP7zsV6FIUdujcnESP4jvw.jpeg" /><figcaption>Conference Room Exterior</figcaption></figure><p>The first phase of construction was completed in May 2017. The incubator is a renovated 10,000 square feet space within a former Owens-Corning manufacturing space. Space consists of a shared, affordable, flexible laboratory, chemistry suite, equipment room, and three BSL-2 rooms. We aim to house up to twelve (12) early-stage companies. Ample space is available for the adjacent expansion</p><p>Mansfield Bio-Incubator is conveniently located halfway between Boston and Providence. We are about 0.7 miles from the Mansfield Train Station (Providence/Stoughton MBTA Commuter Rail line), with the shuttle service available, and about 3 miles from the Rt 95 — Rt 140 exit.</p><p><strong>A Resident Entrepreneur of the Bio-Incubator will have access to the following:</strong></p><p>· Shared laboratory instrumentation, equipment, and procedure rooms (BSL2, chemistry, refrigeration)</p><p>· Conference rooms and meeting lounges, co-working space, and private offices</p><p>· Shared kitchen and cafeteria area. Shared administrative support and business equipment, including copiers/scanners/faxes*</p><p>· Free mailing address and postal services including package receiving</p><p>· Wired and wireless internet connectivity</p><blockquote>Mansfield Bio-Incubator is a 501(c)(3) non-profit that supports your community and the community needs your support.</blockquote><blockquote>We are seeking private and corporate sponsors!</blockquote><p><a href="https://www.bioinc.org/">Home</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=17d2d645dfd0" width="1" height="1" alt=""><hr><p><a href="https://medium.com/labmate/new-mansfield-ma-incubator-opens-doors-to-life-science-entrepreneurs-17d2d645dfd0">New Mansfield, MA Incubator Opens Doors to Life Science Entrepreneurs</a> was originally published in <a href="https://medium.com/labmate">LabMate</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[CRISPR and Machine Learning]]></title>
            <link>https://medium.com/labmate/crispr-and-machine-learning-7b4ccd03b523?source=rss----85079c8483e6---4</link>
            <guid isPermaLink="false">https://medium.com/p/7b4ccd03b523</guid>
            <category><![CDATA[science]]></category>
            <category><![CDATA[machine-learning]]></category>
            <category><![CDATA[startup]]></category>
            <category><![CDATA[crispr]]></category>
            <category><![CDATA[genetics]]></category>
            <dc:creator><![CDATA[LabMate]]></dc:creator>
            <pubDate>Fri, 11 Aug 2017 14:57:02 GMT</pubDate>
            <atom:updated>2017-08-11T14:57:01.928Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*7EHUMNLMiVFlcw5ch9Hg8Q.jpeg" /></figure><blockquote><strong><em>Note From LabMate:</em></strong><em> Our content series seeks to showcase the expertise of senior trainees and industry professionals. LabMate minimally edits content and posts do not undergo formal peer review. You can hire all experts on our platform: </em><a href="http://www.labmate.us/"><em>www.labmate.us</em></a></blockquote><h3>CRISPR and Machine Learning</h3><p>There’s been a great deal of buzz lately around the field of gene editing on topics that range from the next generation of precision medicine to major advances in computational biology. The gene editing applications under development are fascinating and positioned to make a broad impact on science and healthcare. These new technologies come with unique challenges, and moving past the obstacles has turned out to be just as exciting as the initial problems.</p><p>At the center of all the buzz is CRISPR/Cas9, a system borrowed from bacteria now considered the poster child of gene editing (Salsman and Dellaire 2017). Technology to modify specific locations on genomes has never been available before the discovery of the CRISPR/Cas9 system. The applications are broad and include medicine, agriculture, and the ability to control disease-carrying insects (Barrangou and Doudna 2016). CRISPR/Cas9 is the system of choice to modify DNA. Some of the most exciting prospects are in the field of medicine where potential solutions are being developed for health problems that previously seemed hopeless. Combatting antibiotic-resistant bacteria is one health issue with very few potential solutions. Studies show hope that gene-editing might be a good solution. Academic groups from Rockefeller University and North Carolina demonstrated that sequence specific antibiotics that use CRISPR/Cas9 effectively eliminate multi-drug resistant bacterial infections. This type of antibiotic is more potent than traditional broad spectrum antibiotics and is a better choice because it kills only the pathogenic bacteria (Beisel, Gomaa et al. 2014, Bikard, Euler et al. 2014).</p><p>Rare monogenic disease is another healthcare domain with unmet needs and few solutions on the horizon. Co-inventors of CRISPR/Cas9, Dr. Jennifer Doudna, a professor of Chemistry and Molecular and Cellular Biology at UC Berkeley and Dr. Emmanuelle Charpentier, director of the Max Planck Institute for Infection Biology have focused their research efforts on correcting disease-causing single gene mutations. Both are founders of companies that are developing therapeutics for monogenic diseases. Dr. Charpentier is a co-founder of CRISPR Therapeutics headquartered in Basel, Switzerland with satellite operations in Cambridge, Massachusetts and London. CRISPR Therapeutics has several drugs in their pipeline including treatments for hemophilia and Duchenne muscular dystrophy.</p><p>Dr. Doudna is a co-founder of Intellia Therapeutics located in Cambridge, Massachusetts. Like CRISPR Therapeutics, Intellia is also working on treatments that permanently edit disease-associated genes in humans using the CRISPR/Cas9 system. Intellia also has several rare disease treatments in their pipeline including a drug for Transthyretin Amyloidosis (ATTR). This disorder has varying frequencies depending on genetic lineage. West Africans have the highest percent effected at 5% of the population. Also in their pipeline is a treatment for Alpha-1 Antitrypsin Deficiency (AATD), which effects 1 in every 2500 Americans.</p><p>In addition to these in-vivo applications, Intellia is working on an ex-vivo approach to therapy that involves editing cells outside of the body. These programs are being developed through their eXtellia division. This therapeutic approach involves removing cells from patients, editing the cells using CRISPR/Cas9, expanding the therapeutically modified cells, and then returning the cells back to patients. Their ex-vivo focus is immuno-oncology and underserved autoimmune disorders.</p><p>Another area of focus for CRISPR/Cas9 therapeutics, that once developed, could undoubtedly save millions of lives is personalized medicine to treat cancer. Cancer diagnostics are more precise now that we have better genetic sequencing and less intrusive biopsy methods. This has contributed to greater clarity on the specific genes that are causing cancers. Better diagnostics in combination with the technology to edit specific sites in the genome will pave the way for personalized medicine in cancer treatments. A recent interview by McKinsey and Company captured this sentiment perfectly (website-1). Dr. Nessan Birmingham, who is founder and CEO of Intellia Therapeutics said:</p><p>“<em>One can envision a time in the not-too-distant future when a patient presents with a genetic disease. Her genome is sequenced, and a genome-editing drug is custom made, targeting her specific mutation. The patient is subsequently treated and potentially cured, in a cost-effective manner. The CRISPR/Cas9 technology has the potential to drive a medical revolution in the near future</em>.”</p><p>The applications for CRISPR/Cas9 are broad and each have their unique challenges. The most common among them is off-target effects. In the early years of the CRISPR/Cas9 technology off-target effects were a major issue. Many researchers found that the guide RNAs that are essential to the system were problematic. Some issues included that the guide RNAs would not always go to the specific location in the genome that was originally intended, or in other words, they would be off-target. This lead to problems such as introducing mutations in the genome because genome editing would occur at an off-target site. Alternatively, sections of the chromosome would translocate to an off-target location (Cho, Kim et al. 2014). At times the off-target sites would be edited at higher frequencies than the intended on-target site (Fu, Foden et al. 2013).</p><p>The off-target issues spurred a new area of research that included analyzing every feature of the guide RNAs and the effects of those features on the target genome (Hsu, Scott et al. 2013, Chari, Mali et al. 2015). Other studies analyzed the aspects of the target site on the genome (Doench, Fusi et al. 2016). The manual methods for doing these studies require trial and error, long hours in the lab, and a large research budget. Dr. Nicolo Fusi from Microsoft research is a leading researcher in the field of gene editing and summed it up nicely when he said:</p><p>“<em>Very few people have the expertise or the resources to do this kind of work</em>.” (website-2)</p><p>The cutting edge CRISPR/Cas9 technology that was developed to overcome the off-target effects arrived when top researchers in the field working at the intersection of machine learning and gene editing started working together. Researchers now have tools that perform the proper analysis for them to help them optimize using the CRISPR/CAS9 system. There are two important aspects of CRISPR/Cas9 that scientists consider when trying to avoid off-target effects. 1) How to optimize the features of the guide RNA and 2) What is the optimal target sequence on the genome. Algorithms have been developed to help researchers answers these questions.</p><p>DeskGen, a company that provides software systems to automate science research developed a tool that helps researchers ask the first important question of CRISPR/Cas9 experiments: How to optimize features of guide RNA. They recently conducted a study to improve on how to optimize guide RNAs and gleaned valuable insights about applying machine learning to this question (website-3). They found that filtering guide RNA designs according to positive and negative predictors was one way to improve the CRISPR/Cas9 system. They also determined that a ridge regression machine learning model was better suited for this task than a neural network model because the neural network model gave less feedback about what it was doing.</p><p>Researchers use algorithms to optimize features of guide RNAs to help them choose the best guide RNAs. They don’t necessarily need to know why certain guide RNAs are better than others. However, they do prefer knowing those details. The ridge regression model better explained what features of a guide RNA contributed to it being the best guide RNA for any given experiment. They also found that the algorithm accurately predicted activity within a species, but became less accurate when applied to different species. This suggests that building algorithms suited to a given species will be the way to go. Although many insights were made, the researchers felt the study was limited by the availability of CRISPR data to feasibly train and test new algorithms. DeskGen has established itself as an innovative company that designs tools for optimizing CRISPR/Cas9 system for gene-editing research. You can learn more about their technology in this interesting article published by BMC Bioinformatics (Hough, Kancleris et al. 2017) or check out their gene editing tools here (website-4).</p><p>Another group consisting of Microsoft Research and academics from the Broad Institute of MIT and Harvard performed an extensive study to evaluate what influences on-target and off-target activity in the CRISPR/Cas9 system. Part of what they studied involved testing the rules that are integrated into the algorithms that identify which guide sequences are optimal. They also looked at large sets of possible guide RNA gene targets and analyzed both guide and gene characteristics in various combinations. What they found was when they used improved on-target activity predictions and combined it with their off-target avoidance metric they could fully optimize the CRISPR/Cas9 system (Doench, Fusi et al. 2016). They developed new and improved rules and incorporated them into a web portal that was launched last year. Azimuth uses a machine learning algorithm to predict outcomes for guide-gene pairs that enable experimental design for gene editing where there currently is no experimental evidence available. (website-5)</p><p>The hype around CRISPR/Cas9 technology may seem relatively new. But, the reality is CRISPR/Cas9 gene editing has been around for a decade and it is in these past few years that it has really reached its stride (Barrangou and Horvath 2017).</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/180/1*RDKsKNmVBMXxwQL4sK3YcQ.jpeg" /></figure><p>Stephanie Allen received her PhD in Molecular Pathology from UCSD with an emphasis in cancer genetics and postdoctoral work in stem cells. She made the leap into the business side of science and has a solid foundation in research and experience with founding start-ups. In her professional life she juggles consulting, and writing. Stephanie is married with two kids. Her family loves being in the water either the pool or the ocean where they all are training for the next swim or water polo event or catching the next wave!</p><p><em>You can hire Dr. Allen on </em><a href="http://www.labmate.us/"><em>LabMate</em></a></p><p>REFERENCES</p><p>Websites</p><p>1. (<a href="http://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/realizing-the-potential-of-crispr)">http://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/realizing-the-potential-of-crispr)</a></p><p>2. <a href="https://blogs.microsoft.com/next/2016/01/18/molecular-biology-meets-computer-science-tools-in-new-system-for-crispr/">https://blogs.microsoft.com/next/2016/01/18/molecular-biology-meets-computer-science-tools-in-new-system-for-crispr/</a>.</p><p>3. (<a href="https://www.deskgen.com/landing/blog/machine-learning-crispr-guide-design)">https://www.deskgen.com/landing/blog/machine-learning-crispr-guide-design)</a></p><p>4. (<a href="https://www.deskgen.com/landing/)">https://www.deskgen.com/landing/)</a></p><p>5. (<a href="https://www.microsoft.com/en-us/research/project/azimuth/?from=http%3A%2F%2Fresearch.microsoft.com%2Fen-us%2Fprojects%2Fazimuth%2F)">https://www.microsoft.com/en-us/research/project/azimuth/?from=http%3A%2F%2Fresearch.microsoft.com%2Fen-us%2Fprojects%2Fazimuth%2F)</a></p><p>Barrangou, R. and J. A. Doudna (2016). “Applications of CRISPR technologies in research and beyond.” Nature biotechnology <strong>34</strong>(9): 933–941.</p><p>Barrangou, R. and P. Horvath (2017). “A decade of discovery: CRISPR functions and applications.” Nature microbiology <strong>2</strong>: 17092.</p><p>Beisel, C. L., A. A. Gomaa and R. Barrangou (2014). “A CRISPR design for next-generation antimicrobials.” Genome biology <strong>15</strong>(11): 516.</p><p>Bikard, D., C. W. Euler, W. Jiang, P. M. Nussenzweig, G. W. Goldberg, X. Duportet, V. A. Fischetti and L. A. Marraffini (2014). “Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials.” Nature biotechnology <strong>32</strong>(11): 1146–1150.</p><p>Chari, R., P. Mali, M. Moosburner and G. M. Church (2015). “Unraveling CRISPR-Cas9 genome engineering parameters via a library-on-library approach.” Nature methods <strong>12</strong>(9): 823–826.</p><p>Cho, S. W., S. Kim, Y. Kim, J. Kweon, H. S. Kim, S. Bae and J.-S. Kim (2014). “Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases.” Genome research <strong>24</strong>(1): 132–141.</p><p>Doench, J. G., N. Fusi, M. Sullender, M. Hegde, E. W. Vaimberg, K. F. Donovan, I. Smith, Z. Tothova, C. Wilen, R. Orchard, H. W. Virgin, J. Listgarten and D. E. Root (2016). “Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9.” Nature biotechnology <strong>34</strong>(2): 184–191.</p><p>Fu, Y., J. A. Foden, C. Khayter, M. L. Maeder, D. Reyon, J. K. Joung and J. D. Sander (2013). “High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells.” Nature biotechnology <strong>31</strong>(9): 822–826.</p><p>Hough, S. H., K. Kancleris, L. Brody, N. Humphryes-Kirilov, J. Wolanski, K. Dunaway, A. Ajetunmobi and V. Dillard (2017). “Guide Picker is a comprehensive design tool for visualizing and selecting guides for CRISPR experiments.” BMC bioinformatics <strong>18</strong>(1): 167.</p><p>Hsu, P. D., D. A. Scott, J. A. Weinstein, F. A. Ran, S. Konermann, V. Agarwala, Y. Li, E. J. Fine, X. Wu, O. Shalem, T. J. Cradick, L. A. Marraffini, G. Bao and F. Zhang (2013). “DNA targeting specificity of RNA-guided Cas9 nucleases.” Nature biotechnology <strong>31</strong>(9): 827–832.</p><p>Salsman, J. and G. Dellaire (2017). “Precision genome editing in the CRISPR era.” Biochemistry and cell biology = Biochimie et biologie cellulaire <strong>95</strong>(2): 187–201.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=7b4ccd03b523" width="1" height="1" alt=""><hr><p><a href="https://medium.com/labmate/crispr-and-machine-learning-7b4ccd03b523">CRISPR and Machine Learning</a> was originally published in <a href="https://medium.com/labmate">LabMate</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[LabMate CEO Named as Finalist for Xconomy Young Innovator Award]]></title>
            <link>https://medium.com/labmate/labmate-ceo-named-as-finalist-for-xconomy-young-innovator-award-58243b42d5ea?source=rss----85079c8483e6---4</link>
            <guid isPermaLink="false">https://medium.com/p/58243b42d5ea</guid>
            <dc:creator><![CDATA[LabMate]]></dc:creator>
            <pubDate>Wed, 09 Aug 2017 13:33:47 GMT</pubDate>
            <atom:updated>2017-08-09T13:33:47.105Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/521/1*ZlZXY6boH2obXJSKqmu77w.png" /></figure><p><a href="http://www.xconomy.com/boston/2017/08/08/xconomy-awards-the-finalists-are/">http://www.xconomy.com/boston/2017/08/08/xconomy-awards-the-finalists-are/</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=58243b42d5ea" width="1" height="1" alt=""><hr><p><a href="https://medium.com/labmate/labmate-ceo-named-as-finalist-for-xconomy-young-innovator-award-58243b42d5ea">LabMate CEO Named as Finalist for Xconomy Young Innovator Award</a> was originally published in <a href="https://medium.com/labmate">LabMate</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Genome editing: past, present and future]]></title>
            <link>https://medium.com/labmate/genome-editing-past-present-and-future-1c7b2712a20d?source=rss----85079c8483e6---4</link>
            <guid isPermaLink="false">https://medium.com/p/1c7b2712a20d</guid>
            <category><![CDATA[science]]></category>
            <category><![CDATA[crispr]]></category>
            <category><![CDATA[research]]></category>
            <category><![CDATA[genetics]]></category>
            <category><![CDATA[biotechnology]]></category>
            <dc:creator><![CDATA[LabMate]]></dc:creator>
            <pubDate>Wed, 02 Aug 2017 13:54:54 GMT</pubDate>
            <atom:updated>2017-08-03T15:45:45.991Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/proxy/0*9aaBe9frz8NP8GWC.jpg" /></figure><blockquote><strong>Note From LabMate:</strong> Our content series seeks to showcase the expertise of senior trainees and industry professionals. LabMate minimally edits content and posts do not undergo formal peer review. You can hire all experts on our platform: <a href="http://www.labmate.us/">www.labmate.us</a></blockquote><h3>Genome editing: past, present and future</h3><p>The past two decades have been one of rapid innovation in gene editing technology. The tools now exist for investigators to manipulate any gene in a diverse range of model organisms and cell types with targeted nucleases. The rapid development of the field has allowed for highly efficient, precise, and now, cost-effective means to manipulate and modify genes precisely for our benefit. It has great potential in biomedical sciences and agricultural biotechnology. Defective genes can be modified to cure diseases; genes can be modified in animals to introduce new beneficial traits and in plants to give increases resistance to diseases and pests. Gene editing has also been used to create genetically modified animals to study diseases.</p><p>Gene editing tools induce a double-stranded break (DSB) at the target site. This DSB is then repaired by either the error-prone non-homologous end joining (NHEJ) or by homologous recombination (HR). Repair by HR requires the presence of a homologous DNA sequence that is used as a template for repair. For the purposes of gene editing, a modified donor DNA is introduced into the cell to act as a template for repair at the target locus. Three major gene-editing nucleases have been developed and employed with great success in organisms such as yeast, fruit fly, worms, zebrafish, sheep, pigs, and cattle.[1–4] These are zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and clustered regularly interspersed short palindromic repeats (CRISPR)/CRISPR-associated system (Cas).</p><p><strong>Zinc Finger Nucleases (ZFNs)</strong></p><p>ZFNs are engineered chimeric proteins consisting of two distinct domains: an N-terminal DNA binding domain made up of three or more Cys2His2 zinc finger motifs and a C-terminal endonuclease domain derived from the <em>Fok</em>I restriction enzyme.[5] Each finger contacts primarily three consecutive bases of DNA in the major groove and confers specificity for a particular DNA triplet. Zinc fingers arranged in tandem bind extended target sequences such that a three-finger protein binds to a 9 bp target. [6] Since the <em>Fok</em>I nuclease functions as a dimer, two ZFNs bind opposite strands of DNA to induce a DSB that is repaired by either NHEJ or HR.</p><p><strong>Transcription activator-like effector nucleases (TALENs)</strong></p><p>The discovery of a class of proteins called transcription activator-like effectors (TALEs), exclusive to a group of plant pathogens, led to the characterization of a novel DNA-binding domain, termed TALE repeats. The TALE repeats comprise of tandem arrays of 33- 35 repeats that bind and recognize extended DNA sequences, with specificity dictated by two hypervariable residues.[6, 7] These TALEs are fused to the endonuclease domain of <em>Fok</em>I (like ZFNs) to function as dimers to cleave their intended target sites.</p><p><strong>Clustered regularly interspersed short palindromic repeats (CRISPR)/CRISPR-associated system (Cas)</strong></p><p>CRISPR-Cas nucleases are derived from an adaptive immune system developed by the bacteria to defend against invading pathogens. The system consists of two components where the single, small guide RNA (sgRNA) is used to achieve site-specific DNA recognition and the Cas9 nuclease cleaves the DNA generating a DSB at the target. A short conserved sequence known as the protospacer-associated motif (PAM) present in the target is required for the endonuclease activity of Cas9. [6]</p><p><strong>Advantages and disadvantages of one over the other</strong></p><p>All the genome-editing tools discussed above have their advantages and disadvantages. There are some advantages for ZFNs in developing clinical therapies. A major advantage of ZFNs is their history and approval as investigational new drugs by the US Food and Drug Administration. ZFNs have been used successfully to knock out a gene, <em>CCR5</em> that is involved in HIV entry in human T-cells (discussed below). ZFNs are smaller than both TALENs and Cas9, the nuclease in the CRISPR/Cas9 system. When delivering gene-editing components inside the patients for <em>in vivo</em> genome editing, the nuclease is packaged inside lentiviral or adeno-associated virus (AAV) vectors. Cas9 is too big to fit in these delivery vectors. While TALENs can be packaged inside the AAVs, the repeats present in TALENs make them unstable and hence challenging to package in viral systems.[8]</p><p>Both ZFNs and TALENs are cumbersome to develop and have shown associated cytotoxicity.[9] On the other side, CRISPR/Cas nucleases do not require engineering novel proteins for each DNA target site. The relative ease with which new sites can be targeted by just altering the short region of sgRNA that provides specificity, makes this tool highly attractive in the field of genome editing. Moreover, since the Cas9 nuclease is not directly coupled to the sgRNA, the system is highly amenable to multiplexing through concurrent use of multiple sgRNAs to induce DSBs at several loci. However, the sgRNA in CRISPR/Cas9 technology must attach to an anchor sequence, typically two Gs. Hence it is somewhat limited than ZFNs and TALENs. Despite limitations, the simplicity and ease of use of CRISPR/Cas system is fast making it the gene-editing tool of choice for researchers.</p><p><strong>Gene editing in humans to treat diseases</strong></p><p>Gene editing technologies hold tremendous promise to treat genetic diseases, where scientists and clinicians can now address the underlying root cause of the disease at the genetic level. Gene editing has the potential to someday mitigate, prevent, or cure genetic diseases. Research is currently underway on clinical applications of gene editing technologies to treat infectious diseases, blood disorders, cancers, eye disorders, lysosomal storage disorders and amyloidosis, to name a few. Many of these clinical trials are designed to assess the safety and effectiveness of using gene-editing tools for therapeutic purposes. Some are discussed below in more details.</p><p><strong>HIV</strong></p><p>The first clinical trial using ZFNs was completed in 2014. The study consisted of 12 patients and used <em>ex vivo</em> gene editing to knock out a gene <em>CCR5</em> in immune cells of patients with HIV enabling them to fight off the infection (ClinicalTrials.gov Identifier: NCT00842634).[10] <em>CCR5</em> encodes a protein on T cells that the HIV virus targets. The modified cells were then injected back into the patients. The results were very encouraging where nearly half of the patients were cleared to stop taking their retroviral drugs by the end of the trial. Since then, nearly 80 patients have been safely treated by this method.[11]</p><p><strong>Hemophilia</strong></p><p>Hemophilia is a genetic disorder where the blood does not clot normally because it lacks sufficient blood clotting proteins. Presently there are no curative therapies for hemophilia. Treatments are meant to mitigate symptoms. The more prevalent form of the disease, Hemophilia A, is caused by a defect in clotting factor VIII while Hemophilia B is caused by absence of clotting factor IX encoded by gene <em>F9</em>. A ZFN based <em>in vivo</em> liver cell genome editing program is in Phase I/II clinical trials for Hemophilia B (ClinicalTrials.gov Identifier: NCT02695160). ZFN-based Hemophilia A editing programs are in preclinical stages.</p><p><strong>β-thalassemia and Sickle Cell Anemia</strong></p><p>Both β -thalassemia and<strong> </strong>sickle cell anemia are caused by mutations in hemoglobin beta (<em>HBB</em>) gene. These mutations affect the survival of normal red blood cells and impair oxygen delivery to tissues causing multisystem damage. Promising preclinical work has been demonstrated using CRISPR, where the mutation in blood cells is corrected <em>ex vivo</em> before returning them to the patients’ bone marrow so that they can produce healthy red blood cells. Phase I/II clinical trials for β-thalassemia are expected to begin by late 2017.</p><p><strong>Leukemia</strong></p><p>In June 2015, a one-year old girl with B cell acute lymphoblastic leukemia (B-ALL) was successfully treated using donor T cells there were edited <em>ex vivo</em> using TALENs. [12] Similarly, earlier this year, two infants with refractory relapsed B-ALL were treated with the TALEN edited T-cells and are reported to be in full remission about a year after treatment.[13] In these cases, TALENs were used to disrupt the <em>CD52</em> gene and the constant region of the T cell receptor α- chain (TRAC).[13]</p><p><strong>Non-small cell lung cancer</strong></p><p>A Phase I clinical trial based out of Sichuan University in China is underway with patients who have metastatic non-small cell lung cancer and for whom chemotherapy, radiation therapy and other treatments have failed.[14] The study design includes extracting T cells from the blood of the patients and using CRISPR/Cas9 to knock out a gene, <em>PD-1</em>. <em>PD-1</em> restricts a cell’s immune response and inadvertently facilitates cancerous growths. The edited cells will be validated to address off-target issues before re-introduction in the patient.</p><p>Clinical trial registries show that a dozen more trials are planned in China using the same methodology. These target breast, prostrate, bladder, kidney and colorectal cancers to name a few.</p><p><strong>Leber Congenital Amaurosis 10</strong></p><p>Leber Congenital Amaurosis 10 (LCA10) is a genetically inherited retinal dystrophy that leads to blindness or severe visual impairment at birth or during the first months of life.[15] A mutation in the <em>CEP290</em> gene is strongly associated with the disease.[16] Genome editing interventions using CRISPRs aim to deliver editing components using AAVs to target cells to facilitate precise editing of the mutation.[17] The initial clinical trials are set to begin soon.</p><p><strong>Lysosomal Storage Disorders (mucopolysaccharidosis)</strong></p><p>Mucopolysaccharidosis (MPS) I and II are genetic disorders in which enzymes α-L-iduronidase and iduronate 2-sulfatase are affected respectively. These enzymes are needed to properly break down glycosaminoglycans (GAGs). Phase I/II clinical trials using AAV-mediated delivery of ZFNs into patient liver cells, are currently underway (<a href="http://www.empowersmpstrial.com/">http://www.empowersmpstrial.com/</a>, <a href="http://mps2study.com/">http://mps2study.com/</a>).</p><p><strong>Transthyretin Amyloidosis (ATTR)</strong></p><p>ATTR is a degenerative disease characterized by a mutation in the <em>TTR</em> gene. This causes accumulation of misfolded transthyretin proteins that accumulate as amyloid patches in multiple organs. Nonhuman primate studies on gene therapy for <em>ATTR</em> is ongoing where CRISPR/Cas9 will be delivered to edit the genes of a patient’s liver cells using lipid nanoparticles (http://www.intelliatx.com/pipeline/).</p><p><strong>Challenges in the way</strong></p><p>Specificity of the gene editing tools is a major concern in the field. Off-target effects arising from gene editing can inactivate essential genes or activate cancer-causing genes. These are generally difficult to detect requiring whole-genome sequencing to rule them out completely. Cas9, the nuclease component of the CRISPR/Cas system has been shown to tolerate upto five mismatches in the sgRNA sequence or a single base difference in the PAM sequence, which is dependent on the number, position, and distribution of the mismatches throughout the sequence.[18] Recent improvements have been made to CRISPRs to reduce off-target cleavage, with the use of paired nickases. The strategy uses a modified Cas9 that makes a nick rather than a DSB on the DNA. Two sgRNAs complementary to the adjacent area on opposite strands of the target site are used along with the modified Cas9. The DSB is then only induced in the target DNA and nicks are introduced at the off-target sites.</p><p>If the genome editing occurs <em>in vivo</em>, more concerns arise. First, the vector that delivers the editing components (AAV in many cases) may remain in the patients’ bodies many years after the injection, eliciting an extensive immune response. While research till date has shown no such responses, this needs to be studied thoroughly. Further, gene-editing technology is not 100% efficient and as such generates a mosaic of edited and unedited cells. It needs to be ensured that enough of the targeted cells are edited and that the delivery vector delivers the gene-editing payload to the correct target.</p><p><strong>Growing concerns</strong></p><p>The simplicity of design and use, and high success rates of the CRISPR/Cas9 technology has generated excitement in the scientific and medical communities. However, this has also brought in some concerns, including the fact that some researchers might be too aggressive using it. In 2015, Chinese scientists attempted to modify <em>HBB</em> gene using non-viable human embryos from local fertility clinics. [19] In February 2016, scientists in London were granted permission to edit the genomes of human embryos for research into genes involved in early development.[20] The edited embryos were to be destroyed after seven days. This approval by the UK Human Fertilization and Embryology Authority (HFEA) represented the world’s first endorsement of such research by a national regulatory authority. The rapidly advancing gene-editing research involving humans raised some serious ethical questions about editing the human germ line for clinical applications. There are concerns that gene editing tools could be used to alter the human germ line before the ramifications are truly considered. To address these concerns, the International Summit on Human Gene Editing co-hosted by U.S. National Academies of Sciences and Medicine, Chinese Academy of Sciences and U.K.’s The Royal Society was convened in 2015. It was rightly observed that gene editing provides to the human species, a much faster means of evolving than Darwinian evolution. Human germ line editing can only be acceptable when its benefits, both to the individuals and to the broader society, exceeded its risks. However the benefits and levels of acceptable risks remain uncertain presently. The future risks of gene editing remain unpredictable where long-term harms may well outweigh the initial benefits. Well-meaning science to produce benefits to the society can unintentionally reproduce social injustices and reinforce racial and ethnic stigmas. The belief that genes influence particular behaviors or traits can lead to pressures to change those genes in the future generations. More worrisome is the thought that consumer demand for particular traits in offspring can lead people to pursue human gene editing methods outside of regulated bodies.</p><p>These issues highlight the immense scope of abuse of the gene editing technology and the need of worldwide participation of governments, institutions and patient advocacy groups to create regulatory frameworks, guidelines and laws within which human gene editing can be performed. Some of the framework has been put in place where currently gene editing (somatic and germ line) can be performed for basic, preclinical and clinical research. In case of somatic gene editing, the patients must be made aware of the risks. Only those patients should be recruited who have the most severe form of the disease and have exhausted all other areas of treatment. The clinical trials must be rigorously evaluated to weigh in on the associated risks and any potential conflict-of-interests.</p><p>In case of germ line editing, many more concerns must be kept in mind including incomplete editing of early-stage embryos causing mosaicism, the harmful effects that edited genetic changes may have when interacting within different genetic backgrounds and environmental influences, the implications of the genetic modification for both the individual and the future generations, the fact that once introduced into the human population, the genetic alterations will be difficult to remove. For human germ line therapies to be viable in the clinic, the basic criteria are that the gene editing efficiencies need to be near 100% and chances of off-target mutagenesis become non-existent. It would be irresponsible to proceed with performing germ line editing and establishing a pregnancy with edited embryos until the safety and efficacy issues are resolved and there is a broad societal consensus about the appropriateness of the proposed applications. Till then, scientists and clinicians across the world continue examining the impact of the gene editing tools on human society.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/183/1*HOaNAtHlMfsmIgFIgd6pow.png" /></figure><blockquote>Dr. Kusumika Mukherjee is currently a research fellow at the Center for Regenerative Medicine at MGH and Harvard. She have been associated with the gene-editing field for over 10 years now, starting with her PhD where she studied off-target effects in ZFNs. She then pursued her postdoctoral training at MGH where she currently applies CRISPRs to generate knock in/out zebrafish disease models and perform functional analysis of the targeted genes with respect to craniofacial morphogenesis.</blockquote><blockquote>You can hire Dr. Mukherjee on <a href="http://www.labmate.us/">LabMate</a></blockquote><p><strong>References</strong></p><p>1. Beumer, K., et al., <em>Efficient gene targeting in Drosophila with zinc-finger nucleases.</em> Genetics, 2006. <strong>172</strong>(4): p. 2391–403.</p><p>2. Tesson, L., et al., <em>Knockout rats generated by embryo microinjection of TALENs.</em> Nat Biotechnol, 2011. <strong>29</strong>(8): p. 695–6.</p><p>3. Bibikova, M., et al., <em>Targeted chromosomal cleavage and mutagenesis in Drosophila using zinc-finger nucleases.</em> Genetics, 2002. <strong>161</strong>(3): p. 1169–75.</p><p>4. Wood, A.J., et al., <em>Targeted genome editing across species using ZFNs and TALENs.</em> Science, 2011. <strong>333</strong>(6040): p. 307.</p><p>5. Lee, M.S., et al., <em>Three-dimensional solution structure of a single zinc finger DNA-binding domain.</em> Science, 1989. <strong>245</strong>(4918): p. 635–7.</p><p>6. Maeder, M.L. and C.A. Gersbach, <em>Genome-editing Technologies for Gene and Cell Therapy.</em> Mol Ther, 2016. <strong>24</strong>(3): p. 430–46.</p><p>7. Bogdanove, A.J. and D.F. Voytas, <em>TAL effectors: customizable proteins for DNA targeting.</em> Science, 2011. <strong>333</strong>(6051): p. 1843–6.</p><p>8. Holkers, M., et al., <em>Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells.</em> Nucleic Acids Res, 2013. <strong>41</strong>(5): p. e63.</p><p>9. Gupta, R.M. and K. Musunuru, <em>Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9.</em> J Clin Invest, 2014. <strong>124</strong>(10): p. 4154–61.</p><p>10. Tebas, P., et al., <em>Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.</em> N Engl J Med, 2014. <strong>370</strong>(10): p. 901–10.</p><p>11. Carroll, D., <em>A Perspective on the State of Genome Editing.</em> Mol Ther, 2016. <strong>24</strong>(3): p. 412–3.</p><p>12. Reardon, S., <em>Leukaemia success heralds wave of gene-editing therapies.</em> Nature, 2015. <strong>527</strong>(7577): p. 146–7.</p><p>13. Qasim, W., et al., <em>Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells.</em> Sci Transl Med, 2017. <strong>9</strong>(374).</p><p>14. Cyranoski, D., <em>Chinese scientists to pioneer first human CRISPR trial.</em> Nature, 2016. <strong>535</strong>(7613): p. 476–7.</p><p>15. den Hollander, A.I., et al., <em>Mutations in the CEP290 (NPHP6) gene are a frequent cause of Leber congenital amaurosis.</em> Am J Hum Genet, 2006. <strong>79</strong>(3): p. 556–61.</p><p>16. Cideciyan, A.V., et al., <em>Centrosomal-ciliary gene CEP290/NPHP6 mutations result in blindness with unexpected sparing of photoreceptors and visual brain: implications for therapy of Leber congenital amaurosis.</em> Hum Mutat, 2007. <strong>28</strong>(11): p. 1074–83.</p><p>17. Ruan, G.X., et al., <em>CRISPR/Cas9-Mediated Genome Editing as a Therapeutic Approach for Leber Congenital Amaurosis 10.</em> Mol Ther, 2017. <strong>25</strong>(2): p. 331–341.</p><p>18. Pattanayak, V., et al., <em>High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity.</em> Nat Biotechnol, 2013. <strong>31</strong>(9): p. 839–43.</p><p>19. Liang, P., et al., <em>CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes.</em> Protein Cell, 2015. <strong>6</strong>(5): p. 363–372.</p><p>20. Callaway, E., <em>UK scientists gain licence to edit genes in human embryos.</em> Nature, 2016. <strong>530</strong>(7588): p. 18.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=1c7b2712a20d" width="1" height="1" alt=""><hr><p><a href="https://medium.com/labmate/genome-editing-past-present-and-future-1c7b2712a20d">Genome editing: past, present and future</a> was originally published in <a href="https://medium.com/labmate">LabMate</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Charles River: World Congress on Animal Models in Drug Discovery & Development]]></title>
            <link>https://medium.com/labmate/charles-river-world-congress-on-animal-models-in-drug-discovery-development-eef74270b170?source=rss----85079c8483e6---4</link>
            <guid isPermaLink="false">https://medium.com/p/eef74270b170</guid>
            <dc:creator><![CDATA[LabMate]]></dc:creator>
            <pubDate>Wed, 19 Jul 2017 13:52:48 GMT</pubDate>
            <atom:updated>2017-07-19T13:52:47.946Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/800/1*UimGRpXU6kKdd4UQq6JuzA.png" /></figure><p>Charles River has proudly partnered with the EBD Group to provide the scientific program for this year’s BioPharm America™ Conference. This exciting two-day program aims to bridge the gap between drug discovery and clinical application. Driven by the bedside-to-bench experience, industry leaders will come together to discuss innovations and breakthroughs in translational tools and methods in drug discovery research and development. Attendees will gain insight into how clinical data can be used to successfully develop the next generation of animal models, tools and technologies that lead to the development of effective therapies.</p><p><strong>Date:</strong> September 26–27, 2017</p><p><strong>Location:</strong> Sheraton Copley Place, Boston</p><p><a href="http://breakthroughs.criver.com/index.html">Home</a></p><blockquote><strong>Note from LabMate:</strong> Charles River is currently offering a complimentary digital pass and the in person conference is being offered at a $900 discount. This is a fantastic opportunity to network with representatives in academia, industry and venture capital.</blockquote><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=eef74270b170" width="1" height="1" alt=""><hr><p><a href="https://medium.com/labmate/charles-river-world-congress-on-animal-models-in-drug-discovery-development-eef74270b170">Charles River: World Congress on Animal Models in Drug Discovery &amp; Development</a> was originally published in <a href="https://medium.com/labmate">LabMate</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[LabMate Featured in Built In Boston]]></title>
            <link>https://medium.com/labmate/labmate-is-featured-in-built-in-boston-bc412afe117a?source=rss----85079c8483e6---4</link>
            <guid isPermaLink="false">https://medium.com/p/bc412afe117a</guid>
            <dc:creator><![CDATA[LabMate]]></dc:creator>
            <pubDate>Tue, 11 Jul 2017 17:13:48 GMT</pubDate>
            <atom:updated>2017-07-11T17:14:57.819Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/682/1*DLrgJFj8NCB4W1-lw6-yeQ.jpeg" /></figure><p><a href="https://lnkd.in/dZNB-Z5">How Boston startup LabMate connects scientists with paying jobs</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=bc412afe117a" width="1" height="1" alt=""><hr><p><a href="https://medium.com/labmate/labmate-is-featured-in-built-in-boston-bc412afe117a">LabMate Featured in Built In Boston</a> was originally published in <a href="https://medium.com/labmate">LabMate</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[7/5/17 Open Call: Gene Editing Expert]]></title>
            <link>https://medium.com/labmate/7-5-17-open-call-gene-editing-expert-498bf1e4340d?source=rss----85079c8483e6---4</link>
            <guid isPermaLink="false">https://medium.com/p/498bf1e4340d</guid>
            <category><![CDATA[crispr]]></category>
            <dc:creator><![CDATA[LabMate]]></dc:creator>
            <pubDate>Wed, 05 Jul 2017 04:23:16 GMT</pubDate>
            <atom:updated>2017-07-05T14:13:01.956Z</atom:updated>
            <content:encoded><![CDATA[<p>We invite experts (postdocs, faculty members, industry professionals) to pitch article ideas in the field of gene editing (with a focus on CRISPR). We are particularly interested in featuring a scientist who has first-hand understanding of the potential of these technologies, but also the technical limitations and frustrations.</p><p><strong>Pitch Format:</strong></p><p>Tell us in a few sentences what you’d like to write about and why you believe you are qualified to write on the subject. You can do so by directly commenting on the open call, by email (info at labmate.us) or by commenting on our Twitter posting. We will reach out to determine if the article idea is a good fit for our open call.</p><p><strong>Compensation:</strong></p><p>Your work will be shared via social media and email newsletter with some of the most innovative companies and scientists in the world. <strong>We will also send you a $20 Amazon Gift Card</strong>. Our goal is to provide scientists a channel to share their expertise, get noticed and raise their <strong>LabMate profiles </strong>to match with great opportunities.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=498bf1e4340d" width="1" height="1" alt=""><hr><p><a href="https://medium.com/labmate/7-5-17-open-call-gene-editing-expert-498bf1e4340d">7/5/17 Open Call: Gene Editing Expert</a> was originally published in <a href="https://medium.com/labmate">LabMate</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[LabMate Invites You to Showcase Your Company]]></title>
            <link>https://medium.com/labmate/labmate-invites-you-to-showcase-your-company-7f7935de0c72?source=rss----85079c8483e6---4</link>
            <guid isPermaLink="false">https://medium.com/p/7f7935de0c72</guid>
            <category><![CDATA[biotechnology]]></category>
            <category><![CDATA[labmate]]></category>
            <category><![CDATA[pharmaceutical]]></category>
            <category><![CDATA[startup]]></category>
            <dc:creator><![CDATA[LabMate]]></dc:creator>
            <pubDate>Wed, 05 Jul 2017 03:36:48 GMT</pubDate>
            <atom:updated>2017-07-05T03:36:47.561Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*SfNgOD3qV73c2TAYly3C5A.png" /></figure><p>Companies of all sizes now have the opportunity to promote their brand through our new showcase series. All submitted showcases are shared via social media and email newsletter with LabMate’s extensive community of scientists and companies. Showcasing is a fantastic way to attract top talent and announce your presence on the<strong> LabMate platform</strong>.</p><p><strong>Suggested areas to showcase:</strong></p><ol><li>Technology, platform or pipeline</li><li>Company Culture — highlight what makes your company great!</li><li>News — events, clinical trial results, fundraising, etc.</li></ol><p>To submit a company showcase, please contact us at info at labmate.us or on our official Twitter account.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=7f7935de0c72" width="1" height="1" alt=""><hr><p><a href="https://medium.com/labmate/labmate-invites-you-to-showcase-your-company-7f7935de0c72">LabMate Invites You to Showcase Your Company</a> was originally published in <a href="https://medium.com/labmate">LabMate</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[LabMate Featured by the Harvard Stem Cell Institute]]></title>
            <link>https://medium.com/labmate/labmate-featured-by-the-harvard-stem-cell-institute-e467c13486ff?source=rss----85079c8483e6---4</link>
            <guid isPermaLink="false">https://medium.com/p/e467c13486ff</guid>
            <dc:creator><![CDATA[LabMate]]></dc:creator>
            <pubDate>Tue, 04 Jul 2017 23:04:50 GMT</pubDate>
            <atom:updated>2017-07-04T23:04:50.065Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/449/0*CqjF_QRwNw9_9C7E.jpg" /></figure><p>“ In May, 2017, the service-based gig economy is coming to a lab near you — a paradigm shift that will get its start in Boston’s thriving biopharmaceutical ecosystem. As the pool of academic tenure-track positions shrinks, federal research dollars tighten, and pharmaceutical companies and investment firms seek to be more nimble in developing products, a solution is being offered through a platform called <a href="http://labmate.us/">LabMate</a>”</p><p><a href="https://hsci.harvard.edu/news/labmate-introduction">https://hsci.harvard.edu/news/labmate-introduction</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=e467c13486ff" width="1" height="1" alt=""><hr><p><a href="https://medium.com/labmate/labmate-featured-by-the-harvard-stem-cell-institute-e467c13486ff">LabMate Featured by the Harvard Stem Cell Institute</a> was originally published in <a href="https://medium.com/labmate">LabMate</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Scientific Insights Sourced From Subject Matter Experts]]></title>
            <link>https://medium.com/labmate/scientific-insights-sourced-from-subject-matter-experts-84c5951ae991?source=rss----85079c8483e6---4</link>
            <guid isPermaLink="false">https://medium.com/p/84c5951ae991</guid>
            <dc:creator><![CDATA[LabMate]]></dc:creator>
            <pubDate>Tue, 04 Jul 2017 14:53:48 GMT</pubDate>
            <atom:updated>2017-07-05T14:14:58.265Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*SfNgOD3qV73c2TAYly3C5A.png" /></figure><p>Towards LabMate’s goal to democratize access to top scientific expertise, we have created this content series to feature articles written by deep subject matter experts on the hottest fields in science. As we go, we will post open calls for pitches for article ideas within pre-determined scientific fields. These open calls will be found here and posted on our official Twitter account.</p><p><strong>Pitch Format:</strong></p><p>Tell us in a few sentences what you’d like to write about and why you believe you are qualified to write on the subject. You can do so by directly commenting on the open call, by email (info at labmate.us) or by commenting on our Twitter posting. We will reach out to determine if the article idea is a good fit for our open call.</p><p><strong>Compensation:</strong></p><p>Your work will be shared via social media and email newsletter with some of the most innovative companies and scientists in the world. <strong>We will also send you a $20 Amazon Gift Card</strong>. Our goal is to provide scientists a channel to share their expertise, get noticed and raise their <strong>LabMate profiles </strong>to match with great opportunities.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=84c5951ae991" width="1" height="1" alt=""><hr><p><a href="https://medium.com/labmate/scientific-insights-sourced-from-subject-matter-experts-84c5951ae991">Scientific Insights Sourced From Subject Matter Experts</a> was originally published in <a href="https://medium.com/labmate">LabMate</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
    </channel>
</rss>